𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment

✍ Scribed by Ajit K. Shah; Richard C. Brundage; Alois Gratwohl; Ronald J. Sawchuk


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
531 KB
Volume
81
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


The objective of this study was to examine the concentrations in blood of cyclosporine (CyA) in rabbits during chronic subcutaneous (sc) administration and to propose a model that describes these data. Ten rabbits received sc CyA at 15 mg/kg daily for 1 week, then at 20 mg/kg twice weekly for 3 weeks, and at 15 mg/kg twice weekly for 7 weeks. Concentrations in blood were obtained weekly during the dosing period, and three to five concentrations were obtained over a 5-week period after dosing was terminated. CyA blood concentration-time (concentration in blood versus time) profiles could not be adequately described by absorption from a single dosing compartment. A two-compartment, sc absorption-site model was postulated. Steady-state concentrations in blood from three additional rabbits that had received CyA at 16.8 micrograms/min as a constant-rate intravenous infusion were added to the data set. A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day-1 (10.0), k21 = 0.0109 day-1 (12.6), ka = 0.0807 day-1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (F is bioavailability), and Vd/F is the apparent volume of distribution of CyA. The interindividual variability in CL/F was estimated as 20.5% (41.2), and the residual variability was 25.8% (15.6). The sc administration of CyA appears to provide slow, but very significant, absorption in rabbits.


πŸ“œ SIMILAR VOLUMES


Pharmacokinetics of pafenolol in the rat
✍ Hans Lenneras; Carl G. RegΓ₯rdh πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 559 KB

The pharmacokinetics of pafenolol, a highly selective /?,-adrenoceptor antagonist, have been studied in starved and unstarved rats. Separate groups received intravenous doses (0.3 and 3.0pmol kg-I) and oral doses (1 and 25pmol kg-I). The systemic clearance of pafenolol was constant in the dose range

A physiologically based pharmacokinetic
✍ Brett A. Howell; Anuj Chauhan πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 893 KB

Physiologically based pharmacokinetic (PBPK) models were developed for design and optimization of liposome therapy for treatment of overdoses of tricyclic antidepressants and local anesthetics. In vitro drug-binding data for pegylated, anionic liposomes and published mechanistic equations for partit

Interferon alfa-2b in combination with r
✍ Regino P. GonzΓ‘lez-Peralta; Deirdre A. Kelly; Barbara Haber; Jean Molleston; Kar πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 215 KB πŸ‘ 3 views

Chronic hepatitis C virus (HCV) infection is usually asymptomatic in children, but significant liver disease may occur. We evaluated the efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chronic HCV. We determined the optimal ribavirin dose in an initial coh

Cartilage damage caused by metal implant
✍ Roel J.H. Custers; Laura B. Creemers; Mattie H.P. van Rijen; Ab J. Verbout; Dani πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 301 KB πŸ‘ 1 views

## Abstract The purpose of the current study was to investigate the feasibility of the application of defect‐size femoral implants in a rabbit model of established cartilage defects and compare this treatment to microfracturing. In 31 New Zealand White rabbits, a medial femoral condyle defect was c